

**YES**

**OR**

**INFORMATION FOR CLINICIANS**

**NO?**

# CHANGING THE FUTURE – PREVENTING THE ALLERGY MARCH

The progressive development of allergy is often referred to as the Allergy March. One child in five faces this difficult journey. Can this march be predicted and prevented?

## ATOPY AND THE VALUE OF AN EARLY ANSWER

Atopy is defined as: “a personal or familial tendency to produce IgE antibodies in response to low doses of allergens, usually protein, and to develop typical symptoms such as asthma, rhinoconjunctivitis or eczema/dermatitis.”\*

“Atopy is the strongest identifiable predisposing factor for development of asthma.”\*\*

## PREVENTION STARTS WITH PHADIATOP INFANT


Phadiatop Infant is an Atopy test especially designed for children up to four years of age. It includes both food and inhalant allergen components based on known prevalence of offending allergens causing atopic disease in the age group.

Phadiatop Infant is the first step in identifying the source of a child’s symptoms. The second step is to discover the causative allergen with an identification profile. Then the proper course of action can be initiated before the allergy march progresses to more severe disease.

\*Reference: Position paper. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force, Allergy 2001; 56: 813-824

\*\*Reference: The Allergy Report (AAAAI) 2000; www.theallergyreport.org


## CHILDREN 0–4 YEARS WITH WHEEZING AND/OR ECZEMA



### Identification example

- Egg white
- Milk
- Peanut
- House Dust Mite
- Cat Dander
- Dog Dander
- Local Pollens (Grass, Tree, Weed)

### IDENTIFICATION OF CAUSATIVE ALLERGEN



## DETECTS MORE THAN 9 OUT OF 10

270 children, up to the age of 4 years, with symptoms of wheezing and/or eczema were investigated in two independent studies (1, 2) using Phadiatop Infant. The children were classified as either atopic or non-atopic by a pediatric allergist prior to UniCAP Phadiatop Infant assay. The following results were obtained:

Final diagnosis	UniCAP Phadiatop Infant					
	Study (1)			Study (2)		
Atopy/Non-	Pos	Neg	Tot	Pos	Neg	Tot
Positive	84	2	86	56	5	61
Negative	4	32	36	14	64	78
<b>Total</b>	<b>88</b>	<b>34</b>	<b>122</b>	<b>70</b>	<b>69</b>	<b>139</b>

	(1)	(2)
Sensitivity:	98%	92%
Specificity:	89%	82%

Reference: (1) Study performed by Dr. R. Halvorsen, Oslo, Norway. Proprietary Information  
(2) Study performed by Dr. A. Fiocchi and Dr. R. Besana, Milan, Italy. Proprietary Information

# Phadiatop<sup>®</sup> Infant



## **PHARMACIA** *Diagnostics*

Pharmacia Diagnostics AB, SE-751 82 Uppsala, Sweden

Tel +46 18 16 30 00, Fax +46 18 14 03 58, e-mail: [marketing.diagnostics@pharmacia.com](mailto:marketing.diagnostics@pharmacia.com)

[www.diagnostics.nu](http://www.diagnostics.nu)

**Head office Sweden** +46 18 16 30 00 **Austria** +43 1 68 05 00 **Belgium** +32 2 727 44 11 **Brazil** +55 11 5508 3000  
**Canada** +1 905 755 3000 **Denmark** +45 32 96 52 00 **Finland** +358 9 852 071 **France** +33 1 30 64 34 00 **Germany** +49 761 47 805-0  
**Great Britain** +44 1 908 60 37 98 **Italy** +39 02 483 81 **Japan** +81 3 5365 8332 **Netherlands** +31 348 49 49 49  
**Norway** +47 24 09 38 00 **Portugal** +351 21 424 92 65 **Spain** +34 93 582 16 16 **Sweden** +46 18 16 30 00  
**Switzerland** +41 1 802 82 00 **Taiwan** +886 2 2516 0925 **United States** +1 800 346 4364 **Other countries** +46 18 16 56 16